Information Provided By:
Fly News Breaks for October 1, 2015
CELG
Oct 1, 2015 | 05:47 EDT
JPMorgan analyst Cory Kasimov upgraded Celgene to Overweight citing an "increasingly attractive" valuation following the recent pullback in shares. The company is one the "most fundamentally sound biotechs" and shares at current levels are "too compelling to remain on the sidelines," Kasimov tells investors in a research note. He keeps a $152 price target for the stock. Celgene closed yesterday up $2.79 to $108.13. Shares are down 8% over the past month.
News For CELG From the Last 2 Days
There are no results for your query CELG